APG Asset Management US Inc. Has $15.94 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

APG Asset Management US Inc. boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 176,618 shares of the medical research company’s stock after purchasing an additional 3,791 shares during the quarter. APG Asset Management US Inc.’s holdings in Edwards Lifesciences were worth $15,940,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Edwards Lifesciences during the second quarter worth about $182,000. Point72 Europe London LLP acquired a new position in Edwards Lifesciences during the second quarter worth about $4,508,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Edwards Lifesciences by 58.5% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 115,167 shares of the medical research company’s stock worth $10,638,000 after acquiring an additional 42,527 shares in the last quarter. Bank of Montreal Can raised its stake in Edwards Lifesciences by 1.7% during the second quarter. Bank of Montreal Can now owns 1,227,199 shares of the medical research company’s stock worth $112,706,000 after acquiring an additional 20,240 shares in the last quarter. Finally, Integral Health Asset Management LLC acquired a new position in Edwards Lifesciences during the second quarter worth about $13,856,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock worth $1,218,138 in the last quarter. 1.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Barclays lowered their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Evercore ISI lowered their target price on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a research note on Thursday, July 25th. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $105.00 to $72.00 in a report on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $79.82.

Edwards Lifesciences Stock Down 1.4 %

EW stock opened at $65.40 on Thursday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The company has a market capitalization of $39.40 billion, a price-to-earnings ratio of 28.19, a PEG ratio of 2.80 and a beta of 1.13. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a fifty day moving average of $69.02 and a 200-day moving average of $82.43.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the company earned $0.66 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.